Literature DB >> 31372969

[International consensus for the screening, diagnosis and treatment of adult patients with substance use disorder and ADHD].

C L Crunelle, W van den Brink, A Schellekens, G van de Glind, Belgisch/Nederlands Icasa Consortium, F Matthys.   

Abstract

BACKGROUND: Substance use disorders (SUD) and attention-deficit/hyperactivity disorder (ADHD) often co-occur in adults. Together, they complicate diagnosis and can negatively influence treatment outcome.<br/> AIM: To develop a practical guide to assist professionals with the screening, diagnosis and treatment of adult patients with SUD and ADHD.<br/>
METHOD: A literature search and a consensus procedure between several international scientific and clinical experts. This manuscript is an adapted and summarized Dutch version of the International consensus statement on screening, diagnosis and treatment of patients with SUD and comorbid ADHD.<br/>
RESULTS: The routine use of adequate screening tools enables ADHD to be detected earlier in adults with SUD. The diagnostic process for ADHD should be initiated as soon as possible in patients with SUD. Integrated treatment, involving a combination of pharmacotherapy and psychotherapy, is preferred. Long-acting stimulants with up-titration to higher dosages may be considered.<br/>
CONCLUSION: Early detection of ADHD in patients with SUD is essential for adequate diagnosis and more effective treatment and follow-up for these patients.

Entities:  

Mesh:

Year:  2019        PMID: 31372969

Source DB:  PubMed          Journal:  Tijdschr Psychiatr        ISSN: 0303-7339


  1 in total

Review 1.  The International Collaboration on ADHD and Substance Abuse (ICASA): Mission, Results, and Future Activities.

Authors:  Geurt Van de Glind; Christoffer Brynte; Arvid Skutle; Sharlene Kaye; Maija Konstenius; Frances Levin; Frieda Mathys; Zsolt Demetrovics; Franz Moggi; Josep Antoni Ramos-Quiroga; Arnt Schellekens; Cleo Crunelle; Geert Dom; Wim van den Brink; Johan Franck
Journal:  Eur Addict Res       Date:  2020-06-29       Impact factor: 3.015

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.